This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Drugs International Small Molecule 
Chemical Biology and Drug Design
JANUARY 20, 2025
ABSTRACT Drug targeting strategies, such as peptidedrug conjugates (PDCs), have arisen to combat the issue of off-target toxicity that is commonly associated with chemotherapeutic small molecule drugs.
187 
Covalent Modifiers
SEPTEMBER 9, 2023
3c00297 Falling in between traditional small molecules and antibodies in size, peptides are emerging as a privileged therapeutic modality, one that can harness the benefits of both small molecule and antibody drugs. Mengmeng Zheng and Jianmin Gao ACS Chemical Biology 2023 DOI: 10.1021/acschembio.3c00297
195
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Covalent Modifiers
JANUARY 13, 2024
Thomas Kodadek Angewandte Chemie International Edition 2024 e202316726 [link] Many of the highest priority targets in a wide range of disease states are difficult-to-drug proteins.
195 
DrugBank
MAY 15, 2024
The road to developing effective drugs is fraught with both promise and challenge, particularly when it comes to what scientists call "undruggable" targets. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.
SCIENMAG: Medicine & Health
MARCH 26, 2024
Credit: Redox Medicine […]
Drug Target Review
JULY 13, 2023
Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development.
98 
Drug Target Review
APRIL 7, 2025
In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drug developers for phase I trials, second only to navigating regulatory compliance (- 38 percent). To qualify as endpoints, biomarkers used in early phases must be relevant to later stages of drug development.
Zobio
AUGUST 26, 2024
As part of an international team, led by HepaRegeniX, ZoBio solved the structure of an inhibitor bound to the kinase MKK4 using a non-classical approach to structural.
Drug Target Review
JULY 6, 2023
1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional small molecules. Unlike traditional drug discovery, which focuses on inhibiting or activating proteins, TPD offers a more precise and efficient way to alter cellular pathways. How does TPD work?
The Pharma Data
JANUARY 19, 2021
Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, “The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. About ALS-4.
The Pharma Data
NOVEMBER 19, 2020
Program has advanced rapidly under an international collaboration of companies led by Sosei Heptares as part of its commitment to socially responsible investing. Sosei Heptares has successfully designed three distinct series of compounds with attractive anti-viral drug-like properties and advanced the most promising molecules.
Drug Target Review
OCTOBER 23, 2024
Technologies for the rapid and efficient testing of small molecules and biologics have greatly accelerated drug discovery. Intermediate-sized molecules such as macrocycles combining the beneficial properties of both small molecules and biologics may enable the targeting of currently undruggable targets.
Practical Cheminformatics
JANUARY 8, 2024
Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023. Most of the LLM activity in the drug discovery space in 2023 was reported as preprints from academic groups. Most of the drug discovery examples were underwhelming. Here’s the structure of Part II.
136 
DrugBaron
JANUARY 31, 2024
Both the cost and the time required for each new drug approval have increased exponentially for decades (aptly tagged ‘Eroom’s Law’, being the inverse of price drops and speed gains in the semiconductor industry). So what about the theoretical basis for the claim that AI can “revolutionise” drug discovery and development?
165 
Drug Target Review
AUGUST 25, 2023
However, in tissues where the 3 Hs are not present, the small molecule has anti-toxicity activity through 1) direct inhibition of the NLRP3 inflammasome, an inflammation starter and perpetuator, and 2) upregulation of the master antioxidant transcription factor, Nrf2. Frontiers in Oncology. doi:10.3389/fonc.2023.1204143
LifeSciVC
JANUARY 16, 2024
The expectation that Pharma will continue buy-ups here is helping to fuel conviction for another strong year ahead for M&A, especially for those acquirers who will rely on inorganic acquisition to build in areas under-represented by internal R&D (e.g., Small molecule GLP1s?
142 
The Pharma Data
NOVEMBER 30, 2020
Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. Chief Executive Officer of Biohaven, said: “We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery. TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,
Drug Target Review
NOVEMBER 6, 2023
To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. 6 In all these examples, an effective backbone drug was first developed, before adding one or more drugs to establish the new regimens.
111 
The Premier Consulting Blog
NOVEMBER 20, 2024
In the case of urgent or immediate public interest, process validation may be conducted concurrently with manufacturing the commercial small molecule or biologic product to expedite product availability for patients. It ensures that a production process consistently yields products of predetermined quality and safety.
The Pharma Data
DECEMBER 20, 2020
ALS-4 is a novel small molecule adopting an anti-virulence (non-antibiotic) approach to address the growing unmet medical needs of infections caused by Staphylococcus aureus. The secondary objective is to assess the pharmacokinetic profile of SAD and MAD of ALS-4 administered orally to healthy subjects. About ALS-4.
Conversations in Drug Development Trends
APRIL 4, 2024
Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016.
Nvidia Developer: Drug Discovery
MARCH 21, 2023
Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. Generate small molecules with specific properties.
Dark Matter Blog
JANUARY 16, 2023
Our terra firma is small-molecule medicines. We want a drug that we understand, whose behavior is predictable, that is inexpensive and reliable to make, and that can be packed into trucks and shipped to your local drugstore. Perhaps those proteins could be reached by jumping upstream to the mRNA that encodes them.
New Drug Approvals
APRIL 18, 2025
2] [3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [4] kg, the preparation of Compound 8A has been previously described in International Publication Number WO2010/125414) were added to the reactor and heated to 85 C. 1] [2] [5] Names Crinecerfont is the international nonproprietary name. [6]
62 
LifeSciVC
APRIL 24, 2024
Is a novel target at the inflection point where enough evidence is available to suggest it may prove to be a compelling drug? and whether a molecule’s pharmacology can help to mitigate safety risk. In order to start building a case for or against a target, I like to start with genetics – first human and then mouse. in liver, in CNS)?
124 
New Drug Approvals
APRIL 2, 2025
1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 2] [6] Suzetrigine is the first medication to be approved by the US Food and Drug Administration (FDA) in this new class of pain management medicines. [2] Suzetrigine CAS 2649467-58-1 Weight Average: 473.4 ESI-MS m/z calc.475.0922,
62 
LifeSciVC
JULY 6, 2023
But they struggled to find a drug candidate that could bind to and stabilize it. Fortunately, Sanofi Genzyme was willing to out license these assets to an internal team including Dr. Hurlbut and Dr. Mark Munson, who was the U.S. I hope that others in our industry maintain a similar focus on innovation.
The Strateos Blog: Drug Discovery
JULY 26, 2022
Strateos had the pleasure of participating with Evariste Technologies in a webinar hosted by 20/15 Visioneers, about cloud lab automation-as-a-service being leveraged to accelerate cycle times for faster drug discovery. This in silico approach can reduce time and increase the probability of successfully identifying clinical drug candidates.
The Pharma Data
DECEMBER 21, 2020
Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe.
The Premier Consulting Blog
JULY 9, 2023
During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).
Broad Institute
OCTOBER 17, 2023
Deik received her bachelor's degree in botany from Connecticut College and immediately went to work at International Paper, a paper manufacturing company, where she engineered trees to grow faster. At 11 years old, she knew she wanted to be a botanist. I run our lipid method, which annotates over 250 different lipids.
98 
Drug Target Review
SEPTEMBER 26, 2024
Cresset delivers software solutions and contract research expertise enabling companies around the world to accelerate their small molecule discovery processes efficiently and effectively. What are the potential benefits associated with using AI to generate new drug candidates? Then comes resource optimisation.
64 
Drug Target Review
APRIL 19, 2024
Identifying new drugs is an extremely complex project. The scientific founders have developed a pioneering method for drug discovery that applies to the research and design of new drugs effective against diseases that are incurable to date. We are now in the preclinical stage of developing a proprietary drug pipeline.
Drug Target Review
JULY 31, 2023
When it came time to graduate, I thought I wanted to go to graduate school in chemistry, but first I took a year abroad and worked as a teacher at the international school in Israel. The goals for Sunesis had such an impact on my current research, as did the early days of thinking about what we call fragment-based drug discovery.
98 
PerkinElmer
FEBRUARY 18, 2021
Industry leaders reveal how high throughput screening is changing in R&D What do you think are the major trends in drug discovery R&D? Small screens are better than large ones. Here, we summarize the top 10 survey findings on drug discovery trends for the top 20 Pharma leaders in R&D. Biologics are booming.
The Pharma Data
JANUARY 31, 2021
. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?, would be the first antibody drug approved to direct a radioisotope into prostate cancer cells, and the first drug approved for the use of 225 Ac in cancer treatment. . or its ability to internalize PSMA.
The Premier Consulting Blog
MAY 31, 2023
As a cornerstone of the drug development process, nonclinical investigational new drug (IND)-enabling studies are essential for supporting first-in-human (FIH) dosing for novel therapeutics. Pharmacology A typical IND-enabling package includes information on the primary, secondary, and safety pharmacology of the drug.
52 
The Pharma Data
OCTOBER 15, 2020
a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.
The Premier Consulting Blog
JANUARY 31, 2023
Food and Drug Administration (FDA) adopted an addendum to the guidance titled “ S1B(R1) Testing for Carcinogenicity of Pharmaceuticals ,” which had previously been finalized by the International Council for Harmonization (ICH). On November 1, 2022, the U.S. However, the quality and relevance of that data can vary.
Sygnature Discovery
JUNE 17, 2024
At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. We advocate a collaborative approach, engaging both with our clients and within our internal team. Membrane Proteins: Examples include cell surface receptors, GPCRs, and transporters.
The Pharma Data
MAY 15, 2023
Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC and TTM Capital.
The Pharma Data
NOVEMBER 1, 2020
CAMBRIDGE, England–( BUSINESS WIRE )– Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect. 2, 2020 08:00 UTC. This press release features multimedia.
The Pharma Data
OCTOBER 14, 2020
International Dial-in Number: (210) 874-7715. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Time : 4:30 p.m. Domestic Dial-in Number : (866) 913-8546.
Agency IQ
NOVEMBER 10, 2023
To address these data gaps, OPQ is intended to provide FDA insight on quality throughout the lifecycle of products including new drugs, generics, and over-the-counter medications. What the offices will focus on: OPQA I and II are set to focus on small-molecule product assessments.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content